Table 4. Osteopontin variant immunohistochemistry and clinicopathologic variables.
| Polish cohort | ER status | PR status | Her2 status | BRCA1 status | Family history | Tumor stage N | Tumor stage T | |
|---|---|---|---|---|---|---|---|---|
|
OPNc nucl.int. | ||||||||
| Correlation | 0.07331 | 0.00433 | −0.00701 | 0.14347 | 0.05927 | 0.21711 | 0.14069 | |
| P-value | 0.263 | 0.9473 | 0.9183 | 0.073 | 0.4267 | 0.0006 | 0.0267 | |
|
N |
235 |
235 |
217 |
|
157 |
182 |
248 |
248 |
|
OPNc nucl.per. | ||||||||
| Correlation | −0.07118 | −0.04898 | 0.07376 | 0.17555 | 0.08196 | 0.10875 | 0.08009 | |
| P-value | 0.27772 | 0.4549 | 0.2793 | 0.0279 | 0.2713 | 0.0874 | 0.2043 | |
|
N |
235 |
235 |
217 |
|
157 |
182 |
248 |
248 |
|
Exon 4 cyt.int. | ||||||||
| Correlation | −0.03726 | 0.00904 | 0.11273 | 0.11684 | 0.07928 | 0.1472 | 0.21118 | |
| P-value | 0.5698 | 0.8904 | 0.0977 | 0.145 | 0.2874 | 0.0204 | 0.0008 | |
|
N |
235 |
235 |
217 |
|
157 |
182 |
248 |
248 |
|
Exon 4 cyt.per. | ||||||||
| Correlation | −0.00177 | −0.07063 | 0.14513 | 0.19729 | 0.08401 | 0.15886 | 0.13067 | |
| P-value | 0.9785 | 0.2809 | 0.0326 | 0.0133 | 0.2595 | 0.0122 | 0.0398 | |
|
N |
235 |
235 |
217 |
|
157 |
182 |
248 |
248 |
|
Tumor stage
T | ||||||||
| Correlation | −0.05872 | −0.00674 | −0.04282 | −0.01138 | 0.08799 | 0.20622 | — | |
| P-value | 0.4137 | 0.9253 | 0.5682 | 0.8954 | 0.2701 | 0.001 | — | |
|
N |
196 |
196 |
180 |
|
136 |
159 |
248 |
— |
|
Tumor stage
N | ||||||||
| Correlation | −0.21586 | −0.18042 | −0.03603 | 0.01182 | −0.10732 | — | — | |
| P-value | 0.0024 | 0.0114 | 0.6311 | 0.8914 | 0.1781 | — | — | |
|
N |
196 |
196 |
180 |
|
136 |
159 |
— |
— |
|
Family history | ||||||||
| Correlation | 0.30712 | 0.29218 | 0.11734 | 0.43464 | — | — | — | |
| P-value | <0.0001 | 0.0002 | 0.1395 | <0.0001 | — | — | — | |
|
N |
162 |
162 |
160 |
|
135 |
— |
— |
— |
|
BRCA1 status | ||||||||
| Correlation | −0.05872 | −0.00476 | 0.24007 | — | — | — | — | |
| P-value | 0.4137 | 0.9545 | 0.0044 | — | — | — | — | |
|
N |
196 |
146 |
139 |
|
— |
— |
— |
— |
|
Her2 status | ||||||||
| Correlation | 0.05843 | 0.1501 | — | — | — | — | — | |
| P-value | 0.4257 | 0.0398 | — | — | — | — | — | |
|
N |
188 |
188 |
— |
|
— |
— |
— |
— |
|
PR status | ||||||||
| Correlation | −0.05872 | — | — | — | — | — | — | |
| P-value | 0.4137 | — | — | — | — | — | — | |
| N | 196 | — | — | — | — | — | — | |
| Swedish cohort | PR status | ER status | Her2 status | Cyclin D | Cyclin E | Cyclin B | Cyclin A | Ki-67 |
|---|---|---|---|---|---|---|---|---|
|
OPNc nucl.int. | ||||||||
| Pearson correlation | 0.086 | 0.008 | 0.071 | 0.23 | 0.057 | 0.091 | 0.098 | 0.016 |
| Sig. (two-tailed) | 0.109 | 0.889 | 0.194 | 0 | 0.286 | 0.087 | 0.066 | 0.773 |
|
N |
349 |
350 |
340 |
346 |
354 |
351 |
349 |
346 |
|
OPNc cyt.int. | ||||||||
| Pearson correlation | −0.036 | −0.124 | −0.018 | 0.17 | −0.008 | 0.094 | 0.03 | −0.006 |
| Sig. (two-tailed) | 0.509 | 0.021 | 0.737 | 0.001 | 0.886 | 0.079 | 0.579 | 0.912 |
|
N |
348 |
349 |
339 |
345 |
353 |
350 |
348 |
345 |
|
Ki-67 | ||||||||
| Pearson correlation | 0.362 | 0.404 | 0.159 | −0.185 | 0.467 | 0.602 | 0.674 | — |
| Sig. (two-tailed) | 0 | 0 | 0.004 | 0.001 | 0 | 0 | 0 | — |
|
N |
339 |
340 |
334 |
340 |
344 |
341 |
345 |
— |
|
Cyclin A | ||||||||
| Pearson correlation | 0.382 | 0.425 | 0.27 | −0.139 | 0.518 | 0.69 | — | — |
| Sig. (two-tailed) | 0 | 0 | 0 | 0.01 | 0 | 0 | — | — |
|
N |
342 |
343 |
335 |
341 |
347 |
344 |
— |
— |
|
Cyclin B | ||||||||
| Pearson correlation | 0.284 | 0.383 | 0.244 | −0.107 | 0.526 | — | — | — |
| Sig. (two-tailed) | 0 | 0 | 0 | 0.049 | 0 | — | — | — |
|
N |
342 |
343 |
336 |
341 |
350 |
— |
— |
— |
|
Cyclin E | ||||||||
| Pearson correlation | 0.289 | 0.391 | 0.184 | −0.121 | — | — | — | — |
| Sig. (two-tailed) | 0 | 0 | 0.001 | 0.025 | — | — | — | — |
|
N |
346 |
347 |
339 |
343 |
— |
— |
— |
— |
|
Cyclin D | ||||||||
| Pearson correlation | −0.268 | −0.406 | 0.03 | — | — | — | — | — |
| Sig. (two-tailed) | 0 | 0 | 0.582 | — | — | — | — | — |
|
N |
338 |
339 |
330 |
— |
— |
— |
— |
— |
|
Her2 status | ||||||||
| Pearson correlation | 0.23 | 0.236 | — | — | — | — | — | — |
| Sig. (two-tailed) | 0 | 0 | — | — | — | — | — | — |
|
N |
333 |
334 |
— |
— |
— |
— |
— |
— |
|
ER status | ||||||||
| Pearson correlation | 0.585 | — | — | — | — | — | — | — |
| Sig. (two-tailed) | 0 | — | — | — | — | — | — | — |
| N | 349 | — | — | — | — | — | — | — |
Abbreviations: Cyt.int.=cytosolic intensity; Cyt.per.=cytosolic per cent positivity; ER=oestrogen receptor; Her2=human epidermal growth factor receptor 2; Nucl.int.=nuclear intensity; Nucl.per.=nuclear per cent positivity; OPNc=Osteopontin-c; PR=progesterone receptor; sig=significance.
Correlations are displayed between the immunohistochemistry scores for Osteopontin-c or Osteopontin–exon 4 and molecular or clinical readouts. For each pairwise comparison, the Pearson correlation coefficient, the significance according to a two-tailed test and the number (N) of patients analysed are shown. Tumor size was measured as the longest diameter, Ki-67 and cyclin A were assessed as the maximum value of all punches in per cent. Underline=P-values<0.05; bold=moderate correlation.